Citadel Advisors
SPHS

Citadel Advisors’s Sophiris Bio, Inc. SPHS Stock Holding History

Citadel Advisors’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16,080
Closed -$16K – 10394
2019
Q1 		$16K Sell
16,080
-18,081
-53% -$19.4K ﹤0.01% 9109
2018
Q4 		$28K Buy
34,161
+23,080
+208% +$45.4K ﹤0.01% 8650
2018
Q3 		$31K Buy
+11,081
New +$31.5K ﹤0.01% 8929
2018
Q1 		– Sell
-21,608
Closed -$49K – 9258
2017
Q4 		$49K Sell
21,608
-15,113
-41% -$32.9K ﹤0.01% 7641
2017
Q3 		$79K Buy
+36,721
New +$76.1K ﹤0.01% 7096
2016
Q3 		– Sell
-49,176
Closed -$106K – 8331
2016
Q2 		$106K Buy
49,176
+19,402
+65% +$26.8K ﹤0.01% 6168
2016
Q1 		$43K Buy
+29,774
New +$52.5K ﹤0.01% 6286
2013
Q4 		– Sell
-147,404
Closed -$690K – 7510
2013
Q3 		$690K Buy
+147,404
New +$680K ﹤0.01% 3481

Other funds holding SPHS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BO
BRR OpCo Columbus, Ohio $814M AUM 9.75% 1-Year Est. Return
ACM
Alpha Capital Management Austin, Texas $690M AUM 22.82% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors's SPHS Position: Q2 2019 in Review

Citadel Advisors sold out of Sophiris Bio, Inc. (SPHS) in Q2 2019, closing a stake of 16,080 shares — an estimated $16K sold.

Citadel Advisors first reported a position in SPHS in Q3 2013 and held it in 8 quarters. The position peaked at $690K in Q3 2013. 22 funds tracked by Wall St. Rank hold SPHS as of Q2 2019.

  • Citadel Advisors reported no remaining Sophiris Bio, Inc. position as of Q2 2019 after selling out during the quarter.
  • Citadel Advisors sold 16,080 Sophiris Bio, Inc. shares in Q2 2019, an estimated $16K.
  • Citadel Advisors first reported a position in Sophiris Bio, Inc. in Q3 2013 and held it in 8 quarters.
  • Citadel Advisors's Sophiris Bio, Inc. position peaked at $690K in Q3 2013.
  • 22 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q2 2019.

Based on Citadel Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.